PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC (PPDI) [Rocket]

Overview

PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC (PPDI)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
11/08/2021	3/A	PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC (10% Owner) has filed a Form 3/A on Science 37 Holdings, Inc.
10/18/2021	3	PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC (10% Owner) has filed a Form 3 on Science 37 Holdings, Inc.
08/01/2018	4	PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC (10% Owner) has filed a Form 4 on Liquidia Technologies Inc
07/25/2018	3	PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC (10% Owner) has filed a Form 3 on Liquidia Technologies Inc
12/06/2011	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
12/06/2011	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
12/06/2011	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-10	Dec-31-09	Dec-31-08	Dec-31-07	Dec-31-06	Dec-31-05	Dec-31-04	Dec-31-03
Revenues	1,470.6	1,416.8	1,551.4	1,394.9	1,247.7	1,037.1	841.3	727.0
Revenue growth	3.8%	-8.7%	11.2%	11.8%	20.3%	23.3%	15.7%	19.4%
Cost of goods sold	763.3	731.8	807.2	761.5	670.5	550.5	452.8	382.2
Gross profit	707.3	685.0	744.2	633.4	577.2	486.6	388.5	344.8
Gross margin	48.1%	48.4%	48.0%	45.4%	46.3%	46.9%	46.2%	47.4%
Selling, general and administrative	81.9	81.1	68.4	332.6	304.0	251.4	203.2	166.3
Research and development	16.7	13.3	7.6	17.1	5.4	23.4	15.9	74.9
EBITA	186.8	216.9	284.0	229.1	220.0	176.7	140.8	82.4
EBITA margin	12.7%	15.3%	18.3%	16.4%	17.6%	17.0%	16.7%	11.3%
Amortization of intangibles							1.2	1.6
EBIT	186.8	216.9	284.0	229.1	220.0	176.7	139.6	80.8
EBIT margin	12.7%	15.3%	18.3%	16.4%	17.6%	17.0%	16.6%	11.1%
Pre-tax income	188.2	214.5	279.4	247.7	235.5	179.8	138.6	71.2
Income taxes	60.8	62.9	91.5	84.4	78.9	59.9	46.9	24.9
Tax rate	32.3%	29.3%	32.7%	34.1%	33.5%	33.3%	33.8%	35.0%
Earnings from continuing ops	127.3	151.6	187.9	163.3	156.7	119.9	91.7	46.3
Earnings from discontinued ops	-3.7	7.7	-0.4	0.1
Net income	123.7	159.3	187.5	163.4	156.7	119.9	91.7	46.3
Net margin	8.4%	11.2%	12.1%	11.7%	12.6%	11.6%	10.9%	6.4%

Diluted EPS	$1.06	$1.28	$1.56	$1.36	$1.32	$1.03	$0.81	$0.41
Shares outstanding (diluted)	119.7	118.8	120.1	120.0	118.5	116.4	113.8	112.6

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.